Vallon Pharmaceuticalsnasdaqvlonis A Clinical Stage Biopharmaceutical Company Focused On The Development And Commercialization Of Novel Abuse Deterrent Medications For Cns Disordersthe Company S Lead Investigational Product Candidateadairabuse Deterrent Amphetamine Immediate Release Is A Proprietary Abuse Deterrent Formulation Of Immediate Releaseirdextroamphetamine In Development For The Treatment Of Attention Deficit Hyperactivity Disorderadhdand Narcolepsyadair Is Designed To Deter Attempts To Crush And Snort And Provides Barriers To Injection Leveraging The Clinical Success Of Dextroamphetaminewe Are Developing Adair Through A Streamlined 505 B2U Sfda Regulatory Pathwaywhich Is Expected To Obviate The Need For Large Phase 2 And Phase 3 Efficacy And Safety Studiesif Approvedadair Is Expected To Be The First Abuse Deterrentimmediate Release Formulation Of Dextroamphetamine You Can Contact Us Directly At Info Vallon Pharma Com
No conferences found for this company.
| Company Name | Vallon Pharmaceuticals Inc |
| Country |
United States
|
| Address | N/A |
| Telephone | N/A |
| N/A |
